Global Indoleamine 2,3 Dioxygenase 1 Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Indoleamine 2,3 Dioxygenase 1 Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Indoleamine 2,3 Dioxygenase 1 Market Size Growth Rate by Product
  • 1.4.2 BMS-986205
  • 1.4.3 Dcellvax
  • 1.4.4 Epacadostat
  • 1.4.5 F-001287
  • 1.4.6 Galanal
  • 1.4.7 Others
• 1.5 Market by End User
  • 1.5.1 Global Indoleamine 2,3 Dioxygenase 1 Market Size Growth Rate by End User
  • 1.5.2 Aolpecia
  • 1.5.3 Cervical Cancer
  • 1.5.4 Gastric Cancer
  • 1.5.5 Glioma
  • 1.5.6 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Indoleamine 2,3 Dioxygenase 1 Market Size
  • 2.1.1 Global Indoleamine 2,3 Dioxygenase 1 Revenue 2014-2025
  • 2.1.2 Global Indoleamine 2,3 Dioxygenase 1 Sales 2014-2025
• 2.2 Indoleamine 2,3 Dioxygenase 1 Growth Rate by Regions
  • 2.2.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Regions
  • 2.2.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Indoleamine 2,3 Dioxygenase 1 Sales by Manufacturers
  • 3.1.1 Indoleamine 2,3 Dioxygenase 1 Sales by Manufacturers
  • 3.1.2 Indoleamine 2,3 Dioxygenase 1 Sales Market Share by Manufacturers
  • 3.1.3 Global Indoleamine 2,3 Dioxygenase 1 Market Concentration Ratio (CR5 and HHI)
• 3.2 Indoleamine 2,3 Dioxygenase 1 Revenue by Manufacturers
  • 3.2.1 Indoleamine 2,3 Dioxygenase 1 Revenue by Manufacturers (2014-2019)
  • 3.2.2 Indoleamine 2,3 Dioxygenase 1 Revenue Share by Manufacturers (2014-2019)
• 3.3 Indoleamine 2,3 Dioxygenase 1 Price by Manufacturers
• 3.4 Indoleamine 2,3 Dioxygenase 1 Manufacturing Base Distribution, Product Types
  • 3.4.1 Indoleamine 2,3 Dioxygenase 1 Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Indoleamine 2,3 Dioxygenase 1 Product Type
  • 3.4.3 Date of International Manufacturers Enter into Indoleamine 2,3 Dioxygenase 1 Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Product
• 4.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue by Product
• 4.3 Indoleamine 2,3 Dioxygenase 1 Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Indoleamine 2,3 Dioxygenase 1 Breakdown Data by End User

6 North America

• 6.1 North America Indoleamine 2,3 Dioxygenase 1 by Countries
  • 6.1.1 North America Indoleamine 2,3 Dioxygenase 1 Sales by Countries
  • 6.1.2 North America Indoleamine 2,3 Dioxygenase 1 Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Indoleamine 2,3 Dioxygenase 1 by Product
• 6.3 North America Indoleamine 2,3 Dioxygenase 1 by End User

7 Europe

• 7.1 Europe Indoleamine 2,3 Dioxygenase 1 by Countries
  • 7.1.1 Europe Indoleamine 2,3 Dioxygenase 1 Sales by Countries
  • 7.1.2 Europe Indoleamine 2,3 Dioxygenase 1 Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Indoleamine 2,3 Dioxygenase 1 by Product
• 7.3 Europe Indoleamine 2,3 Dioxygenase 1 by End User

8 Asia Pacific

• 8.1 Asia Pacific Indoleamine 2,3 Dioxygenase 1 by Countries
  • 8.1.1 Asia Pacific Indoleamine 2,3 Dioxygenase 1 Sales by Countries
  • 8.1.2 Asia Pacific Indoleamine 2,3 Dioxygenase 1 Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Indoleamine 2,3 Dioxygenase 1 by Product
• 8.3 Asia Pacific Indoleamine 2,3 Dioxygenase 1 by End User

9 Central & South America

• 9.1 Central & South America Indoleamine 2,3 Dioxygenase 1 by Countries
  • 9.1.1 Central & South America Indoleamine 2,3 Dioxygenase 1 Sales by Countries
  • 9.1.2 Central & South America Indoleamine 2,3 Dioxygenase 1 Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Indoleamine 2,3 Dioxygenase 1 by Product
• 9.3 Central & South America Indoleamine 2,3 Dioxygenase 1 by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 by Countries
  • 10.1.1 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 Sales by Countries
  • 10.1.2 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 by Product
• 10.3 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 by End User

11 Company Profiles

• 11.1 BirchBioMed Inc
  • 11.1.1 BirchBioMed Inc Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 BirchBioMed Inc Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 BirchBioMed Inc Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.1.5 BirchBioMed Inc Recent Development
• 11.2 Bristol-Myers Squibb Company
  • 11.2.1 Bristol-Myers Squibb Company Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Bristol-Myers Squibb Company Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Bristol-Myers Squibb Company Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.2.5 Bristol-Myers Squibb Company Recent Development
• 11.3 Ensemble Therapeutics Corp
  • 11.3.1 Ensemble Therapeutics Corp Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Ensemble Therapeutics Corp Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Ensemble Therapeutics Corp Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.3.5 Ensemble Therapeutics Corp Recent Development
• 11.4 F. Hoffmann-La Roche Ltd
  • 11.4.1 F. Hoffmann-La Roche Ltd Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 F. Hoffmann-La Roche Ltd Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 F. Hoffmann-La Roche Ltd Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.4.5 F. Hoffmann-La Roche Ltd Recent Development
• 11.5 Genentech Inc
  • 11.5.1 Genentech Inc Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Genentech Inc Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Genentech Inc Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.5.5 Genentech Inc Recent Development
• 11.6 Globavir Biosciences Inc
  • 11.6.1 Globavir Biosciences Inc Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Globavir Biosciences Inc Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Globavir Biosciences Inc Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.6.5 Globavir Biosciences Inc Recent Development
• 11.7 Incyte Corp
  • 11.7.1 Incyte Corp Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Incyte Corp Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Incyte Corp Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.7.5 Incyte Corp Recent Development
• 11.8 IO Biotech ApS
  • 11.8.1 IO Biotech ApS Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 IO Biotech ApS Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 IO Biotech ApS Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.8.5 IO Biotech ApS Recent Development
• 11.9 Kyowa Hakko Kirin
  • 11.9.1 Kyowa Hakko Kirin Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Kyowa Hakko Kirin Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Kyowa Hakko Kirin Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.9.5 Kyowa Hakko Kirin Recent Development
• 11.10 Netherlands Translational Research Center BV
  • 11.10.1 Netherlands Translational Research Center BV Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Netherlands Translational Research Center BV Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Netherlands Translational Research Center BV Indoleamine 2,3 Dioxygenase 1 Products Offered
  • 11.10.5 Netherlands Translational Research Center BV Recent Development
• 11.11 NewLink Genetics Corp
• 11.12 Pfizer Inc
• 11.13 Redx Pharma Plc
• 11.14 Regen BioPharma Inc

12 Future Forecast

• 12.1 Indoleamine 2,3 Dioxygenase 1 Market Forecast by Regions
  • 12.1.1 Global Indoleamine 2,3 Dioxygenase 1 Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue Forecast by Regions 2019-2025
• 12.2 Indoleamine 2,3 Dioxygenase 1 Market Forecast by Product
  • 12.2.1 Global Indoleamine 2,3 Dioxygenase 1 Sales Forecast by Product 2019-2025
  • 12.2.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue Forecast by Product 2019-2025
• 12.3 Indoleamine 2,3 Dioxygenase 1 Market Forecast by End User
• 12.4 North America Indoleamine 2,3 Dioxygenase 1 Forecast
• 12.5 Europe Indoleamine 2,3 Dioxygenase 1 Forecast
• 12.6 Asia Pacific Indoleamine 2,3 Dioxygenase 1 Forecast
• 12.7 Central & South America Indoleamine 2,3 Dioxygenase 1 Forecast
• 12.8 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Indoleamine 2,3 Dioxygenase 1 Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details